Cancer Genetics Inc (CGIX) 2.03 $CGIX Cancer Genetics,

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cancer Genetics Inc (CGIX) 2.03 $CGIX

Cancer Genetics, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Updates
GlobeNewswire - Tue Aug 09, 5:59PM CDT
-- Company Reports Quarterly Revenues of $7 million, an increase of 67% over the Second Quarter of 2015
CGIX: 2.03 (-0.13)

Healthcare Stocks' Q2 Earnings on Aug 10: QHC, CDNA & CGIX
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 6:52AM CDT
Here, we take a look at three healthcare stocks scheduled to report their second-quarter figures on Aug 10.
CDNA: 4.66 (-0.13), QHC: 6.15 (-0.05), CGIX: 2.03 (-0.13)

Cancer Genetics to Report Second Quarter Earnings on Wednesday, August 10
GlobeNewswire - Mon Aug 01, 4:00PM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the second quarter on Wednesday, August 10, 2016. The company and key management team members will also hold a live investor conference call and webcast at 8:30 AM Eastern on Wednesday, August 10 2016 to discuss the financial results and company updates.
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. and Sayre Therapeutics Announce Distribution Agreement to Commercialize CGI's Proprietary FDA-cleared Tissue of Origin (TOO(R)) Test Throughout India and South Asia
GlobeNewswire - Thu Jun 23, 7:25AM CDT
-- TOO(R) is the ONLY FDA-cleared test of its type, used to aid in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. to Present at the 2016 LD Micro Invitational Investor Conference
GlobeNewswire - Tue Jun 07, 6:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at LD Micro's Sixth Invitational Conference on Wednesday, June 8, 2016 at 11:00 AM Pacific Time, at the Luxe Sunset Bel Air in Los Angeles, CA.
CGIX: 2.03 (-0.13)

HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
GlobeNewswire - Mon Jun 06, 7:00AM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) ("HTG" , a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3-7, 2016 in Chicago, IL.
HTGM: 2.50 (-0.01), CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Partners with ArcherDX to Offer Archer(R) NGS Assays as a Sequencing Service for Biotech and Pharma
BusinessWire - Thu Jun 02, 7:51AM CDT
ArcherDX, Inc., a leader in NGS-based gene fusion detection, has announced that Cancer Genetics, Inc., (CGI) has become a Certified Service Provider of Archer(R) FusionPlex(R) NGS assays. Additionally, CGI plans to use Archer VariantPlex(TM) assays to identify copy number variants (CNVs) and point mutations in tumor samples and will be testing these assays in cell-free variant detection.
CGIX: 2.03 (-0.13)

Cancer Genetics Announces $5 Million Registered Direct Offering
GlobeNewswire - Fri May 20, 8:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("Cancer Genetics" or the "Company" , an emerging leader in DNA-based cancer diagnostics, today announced that it has entered into definitive agreements with healthcare focused institutional investors for an offering of 2.5 million shares of common stock with gross proceeds of approximately $5 million in a registered direct offering.
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel in Precision Medicine, FOCUS::Lymphoma (TM)
GlobeNewswire - Tue May 17, 6:30AM CDT
-- FOCUS::Lymphoma(TM) panel is being used to power several clinical trials with biotech and pharmaceutical companies, and is now available for use in a clinical setting
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Announces 39% Revenue Increase and Provides Recent Company Highlights
GlobeNewswire - Tue May 10, 4:06PM CDT
-- Company reports record quarterly revenues of $6.1 million, an increase of 39% over Q1 2015 and 11% over Q4 2015
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. to Present at Pioneers 2016 Conference Presented by Joseph Gunnar & Co., LLC
GlobeNewswire - Thu May 05, 6:14AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at the Pioneers 2016 Conference presented by Joseph Gunnar & Co., LLC on Thursday, May 5, 2016 at 8:30 AM Eastern Time, at the New York Palace Hotel in New York City.
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies
GlobeNewswire - Wed May 04, 7:34AM CDT
-- CGI is uniquely positioned to deliver comprehensive immune marker and genomic data in oncology for biopharma partners and clinical centers for both solid and blood cancers
CGIX: 2.03 (-0.13)

Cancer Genetics to Report First Quarter 2016 Financial Results on Tuesday, May 10th
GlobeNewswire - Tue May 03, 6:36PM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 after the market close on Tuesday, May 10, 2016. The company will also hold a live investor conference call and webcast at 5:00 pm Eastern.
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota
GlobeNewswire - Fri Feb 05, 7:00AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Minnesota ("BCBS of Minnesota" . As part of the agreement, the over 2.6 million members of the Blue Cross Blue Shield plan will have access to CGI's cancer diagnostics and genomic testing services.
CGIX: 2.03 (-0.13)

Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use In Clinical Trials, Translational Research, and Therapy Selection For Patients
M2 - Fri Jan 22, 4:20AM CST
* Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially impact up to 60% of all cancer patients
CGIX: 2.03 (-0.13)

Molecular Diagnostics in Cancer Testing 2016 - New Technologies and Applications Being Continually Added
M2 - Wed Jan 13, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/2m62l5/molecular) has announced the addition of the "Molecular Diagnostics in Cancer Testing" report to their offering. Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 6. Reimbursement and Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development 9. Company Profiles Companies Mentioned - Abbott Molecular Diagnostics - Accugenomics, Inc. - Agendia - Ambry Genetics - Biodesix - bioM?rieux - bioTheranostics (AviaraDx) - Cancer Genetics, Inc. - Clarient, Inc. (GE Healthcare) - Counsyl - Flatiron Health - Epigenomics - Exact Sciences Corporation - Exiqon - Genomic Health, Inc. - Genoptix, Inc. (Novartis) - Genmark Diagnostics - Genomictree - HTG Molecular Diagnostics - Invitae - LabCorp - Myriad Genetics, Inc. - Nanostring - Neogenomics - NSTG - Nuvera Biosciences - Orion Genomics - Pathway Genomics - Personal Genome Diagnostics - Quest Diagnostics - Rosetta Genomics Ltd. - Signal Genetics - Source MDx - Wilex, Inc. For more information visit http://www.researchandmarkets.com/research/2m62l5/molecular
SGNL: 0.47 (unch), MYGN: 20.36 (-0.18), DGX: 82.82 (-0.72), HTGM: 2.50 (-0.01), EXAS: 18.47 (-0.46), GHDX: 26.47 (+0.31), CGIX: 2.03 (-0.13), NVS: 78.77 (-0.57)

Cancer Genetics, Inc. (CGI) to Present Results of Collaborative Renal Biopsy and Clear Cell Renal Cell Carcinoma (ccRCC) Studies at the 2016 Genitourinary Cancer Symposium
GlobeNewswire - Wed Jan 06, 5:22PM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company" , an emerging leader in DNA-based cancer diagnostics announced the presentation of results from collaborative studies with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. The first study focuses on actionable diagnostic and prognostic information provided by CGI's proprietary next-generation sequencing panel using renal cancer biopsies. The second study focuses on identification of somatic variants in metastatic clear cell renal cell carcinoma patients. Posters with results of both studies will be presented during the 2016 Genitourinary Cancers Symposium, on January 7-9, 2016 in San Francisco, CA.
CGIX: 2.03 (-0.13)

New Strong Sell Stocks for January 6th
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BCC: 26.24 (-0.51), CARO: 21.45 (-0.87), ACBI: 15.41 (+0.02), CGIX: 2.03 (-0.13), HRB: 21.66 (-2.54)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 11

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 121

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 39

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Matt Hougan Shares Insights on Bitcoin's Potential Surge

Updated Category News Views 165

Understanding Bitcoin's Growth Potential Matt Hougan, the Chief Investment Officer at Bitwise, sheds light on the driving forces behind the burgeoning interest in Bitcoin. He emphasizes concerns over the decline of fiat currencies and noteworthy inflows into Bitcoin ETFs as the catalysts propelling Bitcoin's journey towards new heights. This surge towards potential record...

Continue Reading
Empowering Futures: Access Bank's Commitment to Education

Updated Category News Views 174

Support for Educational Development In recent years, The Access Bank UK Ltd has made significant strides in supporting educational initiatives aimed at transforming lives. This commitment is exemplified by the annual Polo Cup event that they host in collaboration with UNICEF and Fifth Chukker. The Access Bank Cup has become more than just a sporting affair; it is a beacon...

Continue Reading
Gary Brecka's Event Redefines Longevity's Future in L.A.

Updated Category News Views 46

Exploring Longevity: A Day Like No Other Alright, picture this: a convergence of wellness diehards, human performance buffs, and curious minds, all filing into the Peacock Theater in Los Angeles. It's August 16th and they're here for Gary Brecka LIVE. This is no run-of-the-mill wellness seminar; it's an exclusive deep dive into the world of longevity hosted by Sequel...

Continue Reading
Ultragenyx Pharmaceutical and Others Face Challenges in Ratings

Updated Category News Views 164

Stock Market Overview This morning, U.S. stock futures indicated a downward trend, with the Dow futures decreasing by about 100 points. Given the numerous fluctuations in the market recently, this drop is indicative of the challenges many companies are facing. Ultragenyx Pharmaceutical Inc Performance Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have sharply...

Continue Reading
Netflix's Future: Overcoming Slower Subscriber Growth Strategies

Updated Category News Views 185

Analyzing Netflix's Subscription Growth and Future Strategies Netflix, a leading name in streaming services, is facing a potential slowdown in subscriber additions. Analysts suggest that the streaming giant might experience its most modest subscriber growth in the past six quarters as the gains from its recent password-sharing crackdown start to wane. With this shifting...

Continue Reading